This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chambers, H. F. Search for Related Content PubMed PubMed Citation Articles by Chambers, H. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2005, p. 884-888, Vol. 49, No. 3
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.3.884-888.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Evaluation of Ceftobiprole in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus

Division of Infectious Diseases, San Francisco General Hospital, and University of California—San Francisco, San Francisco, California¹

Received 29 July 2004/ Returned for modification 12 October 2004/ Accepted 11 November 2004

Ceftobiprole is a novel broad-spectrum cephalosporin that binds with high affinity to PBP 2a, the methicillin-resistance determinant of staphylococci, and is active against methicillin- and vancomycin-resistant Staphylococcus aureus. Ceftobiprole was compared to vancomycin in a rabbit model of methicillin-resistant S. aureus aortic valve endocarditis. Ceftobiprole and vancomycin were equally effective against endocarditis caused by methicillin-resistant S. aureus strain 76, whereas ceftobiprole was more effective than vancomycin against the vancomycin-intermediate S. aureus strain HIP5836. The activity of ceftobiprole against drug-resistant strains of S. aureus warrants its further clinical development.

This article has been cited by other articles:

• Anderson, S. D, Gums, J. G (2008). Ceftobiprole: An Extended-Spectrum Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin. The Annals of Pharmacotherapy 42: 806-816 [Abstract] [Full Text]  
• Pillar, C. M., Aranza, M. K., Shah, D., Sahm, D. F. (2008). In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. J Antimicrob Chemother 61: 595-602 [Abstract] [Full Text]  
• Noel, G. J., Strauss, R. S., Amsler, K., Heep, M., Pypstra, R., Solomkin, J. S. (2008). Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria. Antimicrob. Agents Chemother. 52: 37-44 [Abstract] [Full Text]  
• Arias, C. A., Singh, K. V., Panesso, D., Murray, B. E. (2007). Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother 60: 594-598 [Abstract] [Full Text]  
• Jacqueline, C., Caillon, J., Le Mabecque, V., Miegeville, A.-F., Hamel, A., Bugnon, D., Ge, J. Y., Potel, G. (2007). In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis Model. Antimicrob. Agents Chemother. 51: 3397-3400 [Abstract] [Full Text]  
• Lodise, T. P. Jr., Pypstra, R., Kahn, J. B., Murthy, B. P., Kimko, H. C., Bush, K., Noel, G. J., Drusano, G. L. (2007). Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects. Antimicrob. Agents Chemother. 51: 2378-2387 [Abstract] [Full Text]  
• Arias, C. A., Singh, K. V., Panesso, D., Murray, B. E. (2007). Time-Kill and Synergism Studies of Ceftobiprole against Enterococcus faecalis, Including {beta}-Lactamase-Producing and Vancomycin-Resistant Isolates. Antimicrob. Agents Chemother. 51: 2043-2047 [Abstract] [Full Text]  
• Bogdanovich, T., Ednie, L. M., Shapiro, S., Appelbaum, P. C. (2005). Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin. Antimicrob. Agents Chemother. 49: 4210-4219 [Abstract] [Full Text]  
• von Eiff, C., Friedrich, A. W., Becker, K., Peters, G. (2005). Comparative In Vitro Activity of Ceftobiprole against Staphylococci Displaying Normal and Small-Colony Variant Phenotypes. Antimicrob. Agents Chemother. 49: 4372-4374 [Abstract] [Full Text]  
• Vaudaux, P., Gjinovci, A., Bento, M., Li, D., Schrenzel, J., Lew, D. P. (2005). Intensive Therapy with Ceftobiprole Medocaril of Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3789-3793 [Abstract] [Full Text]  
• Madrigal, A. G., Basuino, L., Chambers, H. F. (2005). Efficacy of Telavancin in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant Staphylococcus aureus or Vancomycin-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3163-3165 [Abstract] [Full Text]